DCM
SUPN icon

Davis Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Davis Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140 Buy
+3
New +$144 ﹤0.01% 970

Other funds holding SUPN

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
CNAM
Campbell Newman Asset Management Milwaukee, Wisconsin $1.35B AUM 38.87% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
JIR
James Investment Research Alpha, Ohio $984M AUM 36.03% 1-Year Est. Return

Davis Capital Management's SUPN Position: Q2 2026 in Review

Davis Capital Management opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 3 shares worth $140. The stake represents ﹤0.01% of the portfolio and ranks #970 among its holdings.

58 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Davis Capital Management held 3 shares of Supernus Pharmaceuticals worth $140 as of Q2 2026.
  • Supernus Pharmaceuticals was a new Davis Capital Management position in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2026, its #970 holding.
  • 58 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Davis Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.